3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Carcinoma, Transitional Cell
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Melanoma
2
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Glioblastoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
7
pembrolizumab
6
Radiotherapy
6
Cisplatin
6
Sunitinib
5
Carboplatin
5
Paclitaxel
4
Thymectomy
3
130-nm albumin-bound paclitaxel
3
selinexor
2
lenvatinib
2
fludarabine
2
Taxes
2
Robotic Surgical Procedures
2
Ramucirumab
2
Prednisone
2
Pemetrexed
2
Octreotide
2
Nivolumab
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
Methylprednisolone
2
Imatinib Mesylate
2
Etoposide
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Doxorubicin
2
Chemoradiotherapy
2
Celecoxib
2
zimberelimab
1
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymoma
×
regorafenib
×
Thoracic
×
Clear all
NCT02307500
2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2
Completed
82 enrolled